BD has settled on a new name for its new company, the independent spinout that will house its billion-dollar diabetes care business. Embecta is set to launch as its own, publicly traded brand in the…
Goldfinch Bio hopes a 13-year Ardelyx veteran can help it advance mid-stage and early-phase kidney disease drugs. Jeff Jacobs joins the Gilead-partnered biotech after helping Ardelyx get its own…
Seattle biotech Cyrus Biotechnology announced this morning that it closed an $18 million Series B — and landed an acquisition to boot. The biotech, which has an in-house software program for biologics…
Keytruda made history seven years ago as the first anti-PD-1 therapy approved in the US, winning an OK in metastatic melanoma. The drug has since become a megablockbuster, and on Friday earned a new…
Bolt Bio’s BDC-1001, an antibody conjugate drug designed to amp up the body’s innate immune system response to tumors, posted a single partial response in a Phase I/II study in patients with HER2…
As fast as COVID-19’s omicron variant is predicted to spread, diagnostics companies hope to be faster by quickly developing new tests to detect the coronavirus’ newest mutations. Just 48 hours after…
Adicet Bio has laid down a marker for the nascent gamma delta CAR-T cell therapy space, reporting its off-the-shelf candidate ADI-001 triggered responses in a small clinical trial of B-cell non…
Clinical trials had more Black patients in the past decade, but studies of investigational drugs continued to underrepresent patients from Asian, Latino, Hispanic and Native American backgrounds.…
Researchers at the University of Maryland say a genetic variant linked to the Old Order Amish community in Pennsylvania reduce levels of LDL cholesterol and a blood-clotting protein. The findings…
Aeglea BioTherapeutics found itself in an unusual position going into the readout from its pivotal rare disease clinical trial. With Aeglea expected to meet its primary endpoint, investors were…
